National Cancer Institute (nci)

This phase 2 trial tested the drug olaparib (Lynparza) in people with advanced pancreatic acinar cell carcinoma, a rare and aggressive pancreatic cancer. Only 5 participants were enrolled before the study was terminated. Participants took olaparib pills twice daily for up to 2 ye…

This early-phase trial tested a new type of immunotherapy for people with advanced cancers that carry a specific protein called KK-LC-1. The treatment involved collecting a patient's own immune cells, modifying them in the lab to better recognize and attack cancer cells, and infu…

This early-phase trial tested a combination of two drugs—icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)—in people with a rare, aggressive form of breast cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumo…

This phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with certain rare cancers—wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer—that had not responded to other treatments. Participants received daily injections for…

This phase 2 trial aimed to see if adding the targeted drug binimetinib to the standard hormone therapy fulvestrant could help people with a certain genetic change (NF1) in hormone receptor-positive breast cancer that has spread. Only one person enrolled before the study was term…

This early-phase trial tested a new drug called KRT-232 combined with three standard myeloma treatments (carfilzomib, lenalidomide, and dexamethasone) in 35 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goals were to check safety and …

This early-phase trial tested two lab-made antibodies, magrolimab and mogamulizumab, together in people with a type of T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to prior treatments. The goal was to find the best dose and see if…

This early-phase trial tested a new approach for people with advanced gastrointestinal cancers (like pancreatic, colon, or stomach cancer) that have a specific genetic change called KRAS G12D. Researchers took participants' own white blood cells, genetically modified them in the …

This study tested a new drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent brain tumors (anaplastic astrocytoma or glioblastoma). The goal was to find safe doses and see if the combination worked better than temozolomide …

This study tested a combination of chemotherapy drugs for people with stomach cancer that has spread inside the belly. The treatment involved giving one drug directly into the abdomen and through a vein, plus a second drug taken by mouth. The goal was to see if this approach coul…

This study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…

This early-phase study tested two immunotherapy drugs, ipilimumab and nivolumab, together in people with HIV who also had advanced solid tumors or Hodgkin lymphoma. The goal was to find the safest dose and see if the combination could shrink tumors. The trial was stopped early, b…

This early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and targeted therapy could help people with HER2-positive breast cancer that has spread. The trial included 190 adults with advanced disease. Unfortunately, the study was stopped early, …

This study tested a drug called sacituzumab govitecan in people with ovarian, endometrial, or cervical cancer that returned after at least two rounds of standard treatment. The goal was to see if the drug could shrink or eliminate tumors. The study was terminated early with only …

This study tested a combination of two drugs, VB-111 and nivolumab, in 14 adults with colorectal cancer that had spread to the liver. The goal was to see if the treatment was safe and could shrink tumors. The trial was terminated early, but researchers collected data on side effe…

This early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…

This study looked at whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with nasopharyngeal cancer that has returned or spread. The trial was planned for many participants but was stopped early, so only 15 people took part. Because of the e…

This early-phase trial tested the drug navtemadlin (AMG 232) in 32 adults with glioblastoma, an aggressive brain cancer. The study aimed to find the safest dose and see how much drug reaches the tumor. It was stopped early, but the goal was to control tumor growth, not cure the d…

This study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that had spread and had specific gene changes (PIK3CA or PTEN). The goal was to see if the combination was safe and could hel…

This study tested a drug called obeticholic acid (OCA), which is similar to a natural bile acid, to see if it could safely reduce the number of polyps in the intestines of people with familial adenomatous polyposis (FAP). FAP is a rare genetic condition that causes many polyps an…

This early-phase study tested a gene therapy for people with metastatic cancer that makes a protein called CEA. Researchers took white blood cells from each patient, added a new gene to help them attack CEA-positive tumors, and infused the modified cells back after chemotherapy. …

This early-stage study tested a new way to treat ovarian, fallopian tube, or primary peritoneal cancer that had returned or stopped responding to standard treatments. Researchers took a type of white blood cell (monocytes) from each participant, stimulated them with two immune-bo…

This study tested a new drug called BMS-986253 for people with myelodysplastic syndromes (MDS), a group of bone marrow cancers. The goal was to see if the drug was safe and effective, either alone or with another treatment. Only 2 adults joined before the study was stopped early,…

This study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…

This study tested a combination of three drugs—nivolumab, tadalafil, and vancomycin—in adults with liver cancer or liver tumors that spread from colorectal or pancreatic cancer. The goal was to see if the treatment could shrink tumors. The trial was stopped early, but the approac…

This study explored whether analyzing sweat from fingerprints using a special camera could quickly detect COVID-19. Researchers enrolled 66 adults who had tested positive or negative for COVID-19 within the past week. Participants provided a fingerprint sweat sample and a blood s…

This study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …

This study aimed to screen cancer patients for genetic markers that affect how they respond to drugs. The goal was to use this information to quickly match patients to the right clinical trials and drug doses, saving time. Only 8 adults were enrolled before the study ended early.…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…

This study aimed to collect tumor tissue from patients with lung, chest, ovarian, or bladder cancers, or those who had adoptive cell therapy, within three hours after death. The goal was to analyze the tissue to learn more about how cancer starts, spreads, and changes over time. …

This study reviews medical records of 42 people with familial adenomatous polyposis (FAP) who previously took the drug erlotinib. The goal is to see how quickly their disease progressed after stopping the drug. No new treatment is given; researchers simply look at past endoscopy …